The house dust mite is a major cause of respiratory allergy worldwide. The management of mite allergy is based on avoidance measures, drug treatment, and allergen immunotherapy, but only allergen immunotherapy is able to modify the natural history of the disease. Injectable subcutaneous immunotherapy was introduced a century ago, while sublingual immunotherapy was proposed in the 1980s and emerged in the ensuing years as an effective and safe option to subcutaneous immunotherapy. However, the quality of the extracts to be used in allergen immunotherapy is crucial for the success of treatment. The mite extract for sublingual immunotherapy known as Staloral 300 was developed to offer optimal characteristics concerning the mite culture medium, standardization, and allergen dose. Double-blind, placebo-controlled trials with Staloral 300 have provided a substantial part of the clinical evidence analyzed in a meta-analysis of the efficacy of allergen immunotherapy in mite-induced rhinitis and asthma. Safety and tolerability are very good, mild local reactions in the mouth being the most common side effect. This makes it feasible to carry out sublingual immunotherapy for the 3-5-year duration needed to achieve long-lasting tolerance to the specific allergen. The performance of Staloral 300 may provide optimal conditions for an effective and safe sublingual immunotherapy in patients with mite-induced respiratory allergy.

Requirements for acquiring a high-quality house dust mite extract for allergen immunotherapy / F., Frati; C., Incorvaia; M., David; S., Scurati; S., Seta; G., Padua; E., Cattaneo; Cavaliere, Carlo; A., Di Rienzo; I., Dell'Albani; P., Puccinelli. - In: DRUG DESIGN, DEVELOPMENT AND THERAPY. - ISSN 1177-8881. - ELETTRONICO. - 6:(2012), pp. 117-123. [10.2147/DDDT.S30908]

Requirements for acquiring a high-quality house dust mite extract for allergen immunotherapy.

CAVALIERE, CARLO;
2012

Abstract

The house dust mite is a major cause of respiratory allergy worldwide. The management of mite allergy is based on avoidance measures, drug treatment, and allergen immunotherapy, but only allergen immunotherapy is able to modify the natural history of the disease. Injectable subcutaneous immunotherapy was introduced a century ago, while sublingual immunotherapy was proposed in the 1980s and emerged in the ensuing years as an effective and safe option to subcutaneous immunotherapy. However, the quality of the extracts to be used in allergen immunotherapy is crucial for the success of treatment. The mite extract for sublingual immunotherapy known as Staloral 300 was developed to offer optimal characteristics concerning the mite culture medium, standardization, and allergen dose. Double-blind, placebo-controlled trials with Staloral 300 have provided a substantial part of the clinical evidence analyzed in a meta-analysis of the efficacy of allergen immunotherapy in mite-induced rhinitis and asthma. Safety and tolerability are very good, mild local reactions in the mouth being the most common side effect. This makes it feasible to carry out sublingual immunotherapy for the 3-5-year duration needed to achieve long-lasting tolerance to the specific allergen. The performance of Staloral 300 may provide optimal conditions for an effective and safe sublingual immunotherapy in patients with mite-induced respiratory allergy.
2012
allergen extracts, asthma, house dust mite, rhinitis, sublingual immunotherapy
01 Pubblicazione su rivista::01a Articolo in rivista
Requirements for acquiring a high-quality house dust mite extract for allergen immunotherapy / F., Frati; C., Incorvaia; M., David; S., Scurati; S., Seta; G., Padua; E., Cattaneo; Cavaliere, Carlo; A., Di Rienzo; I., Dell'Albani; P., Puccinelli. - In: DRUG DESIGN, DEVELOPMENT AND THERAPY. - ISSN 1177-8881. - ELETTRONICO. - 6:(2012), pp. 117-123. [10.2147/DDDT.S30908]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/763831
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 11
social impact